PF-Atlas › Clinical Trials › NCT07486206

Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial

Standard ILD Follow-Up Pathway · Not specified

Registry ID
NCT07486206
Phase
Not specified
Status
Active, not recruiting
Drug / intervention
Standard ILD Follow-Up Pathway
Sponsor
Hospital de Granollers
Start
2026-03-09
Enrollment
152
Locations
1

About this trial

The OPTIMIZE-ILD-2 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated follow-up pathway on patients with established interstitial lung disease (ILD). In routine clinical practice, follow-up workflows for ILD are frequently fragmented, requiring multiple hospital visits for pulmonary function tests, laboratory analysis, treatment administration, and consultations with various specialists, which increases the burden for both patients and caregivers. This study compares the standard follow-up care against an optimized circuit where all routine monitoring procedures and interdisciplinary consultations are pre-bundled and scheduled within a single, coordinated hospital visit. All eligible patients under active ILD follow-up are includ

View NCT07486206 on ClinicalTrials.gov →

Medical disclaimer. This page summarizes public trial data for NCT07486206 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.